AOD9604
AOD9604 is a peptide, indexed here under Growth hormone secretagogues.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Growth hormone secretagogues |
| CAS registry number | 221231-10-3[1] |
| PubChem CID | 71300630[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C78H123N23O23S2[1] |
| Molecular weight | 1815.1 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
AOD9604 is a fragment of human growth hormone rather than a secretagogue acting at the ghrelin receptor, and it is indexed in this class because it is researched and searched alongside those compounds. A 2001 Endocrinology paper reports the effects of human growth hormone and its lipolytic fragment on lipid metabolism, and a 2000 Hormone Research paper reports metabolic studies of the synthetic lipolytic domain.
Much of the retrieved set is analytical and anti-doping work rather than efficacy research. A 2015 Drug Testing and Analysis paper reports detection and in vitro metabolism, a 2014 paper in the same journal identifies peptide drugs in unknown pharmaceutical preparations, and a 2013 paper reports that the compound does not influence the World Anti-Doping Agency human growth hormone isoform immunoassay. A 2015 Annals of Clinical and Laboratory Science paper reports an intra-articular injection study with and without hyaluronic acid.
[3, 4, 5, 6, 7, 8]Reported mechanism
A fragment of human growth hormone described in the retrieved records as its lipolytic domain; it is not reported to act at the growth hormone secretagogue receptor.
[3, 4]Stated in the titles of the cited 2001 Endocrinology and 2000 Hormone Research papers.
Targets named in the cited records: lipid metabolism.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
AOD9604 appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- AOD-9604
- hGH fragment 176-191
Where this page sits
Research records
Cited research records for AOD9604, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Compounds indexed next to it
- Ipamorelin — Growth hormone secretagogues
- Hexarelin — Growth hormone secretagogues
Class page: Growth hormone secretagogues. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for AOD9604?
AOD9604 is a fragment of human growth hormone rather than a secretagogue acting at the ghrelin receptor, and it is indexed in this class because it is researched and searched alongside those compounds. A 2001 Endocrinology paper reports the effects of human growth hormone and its lipolytic fragment on lipid metabolism, and a 2000 Hormone Research paper reports metabolic studies of the synthetic lipolytic domain.
Which class is AOD9604 indexed under?
AOD9604 is indexed under Growth hormone secretagogues. Growth hormone secretagogues are compounds that act at the growth hormone secretagogue receptor, the receptor for ghrelin, rather than at the growth hormone releasing hormone receptor.
What does the FDA application register show for AOD9604?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- PubChem Compound Summary for CID 71300630, Aod-9604. PubChem, National Library of Medicine (2026). pubchem:71300630
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:aod-9604
- The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology (2001). pmid:11713213
- Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone research (2000). pmid:11146367
- Detection and in vitro metabolism of AOD9604. Drug testing and analysis (2015). pmid:25208511
- Identification and characterization of peptide drugs in unknown pharmaceutical preparations seized by the Belgian authorities: case report on AOD9604. Drug testing and analysis (2014). pmid:24976118
- AOD-9604 does not influence the WADA hGH isoform immunoassay. Drug testing and analysis (2013). pmid:24124033
- Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Annals of clinical and laboratory science (2015). pmid:26275694
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.